References: 

• 1. Gonatas N, Shy G (1965) Childhood myopathies with abnormal mitochondria. In Proceedings of the Vth International Congress of Neuropathology 100: 606–612.
• 2. Baron M, Kudin AP, Kunz WS (2007) Mitochondrial dysfunction in neurodegenerative disorders. Biochem Soc Trans 35: 1228–1231.    
• 3. DiMauro S (2011) A history of mitochondrial diseases. J Inherit Metab Dis 34: 261–276.    
• 4. Mattson MP, Gleichmann M, Cheng A (2008) Mitochondria in neuroplasticity and neurological disorders. Neuron 60: 748–766.    
• 5. Federico A, Cardaioli E, Da Pozzo P, et al. (2012) Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci 322: 254–262.    
• 6. De Vos KJ, Grierson AJ, Ackerley S, et al. (2008) Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 31: 151–173.    
• 7. Chen H, Chan DC (2009) Mitochondrial dynamics–fusion, fission, movement, and mitophagy–in neurodegenerative diseases. Hum Mol Genet 18: R169–R176.    
• 8. Wang X, Su B, Zheng L, et al. (2009) The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Neurochem 109: 153–159.    
• 9. Büeler H (2009) Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp Neurol 218: 235–246.    
• 10. Park JS, Davis RL, Sue CM (2018) Mitochondrial dysfunction in Parkinson's disease: new mechanistic insights and therapeutic perspectives. Curr Neurol Neurosci Rep 18: 21.    
• 11. Alexiou A, Vlamos P, Volikas K (2010) A Theoretical Artificial Approach on Reducing Mitochondrial Abnormalities in Alzheimer Disease. In Proceedings of the 10th IEEE International Conference on Information Technology and Applications in Biomedicin, IEEE: 1–4.
• 12. Benard G, Karbowski M (2009) Mitochondrial fusion and division: regulation and role in cell viability. Semin Cell Dev Biol 20: 365–374.    
• 13. Zorov DB, Vorobjev IA, Popkov VA, et al. (2019) Lessons from the Discovery of Mitochondrial Fragmentation (Fission): A Review and Update. Cells 8: 175.    
• 14. Sheng ZH (2017) The interplay of axonal energy homeostasis and mitochondrial trafficking and anchoring. Trends Cell Biol 27: 403–416.    
• 15. Lin MY, Sheng ZH (2015) Regulation of mitochondrial transport in neurons. Expe Cell Res 334: 35–44.    
• 16. Mishra P, Chan DC (2016) Metabolic regulation of mitochondrial dynamics. J Cell Biol 212: 379–387.    
• 17. Dickey AS, Strack S (2011) PKA/AKAP1 and PP2A/Bβ>2 regulate neuronal morphogenesis via Drp1 phosphorylation and mitochondrial bioenergetics. J Neurosci 31: 15716–15726.    
• 18. Kuznetsov AV, Hermann M, Saks V, et al. (2009) The cell-type specificity of mitochondrial dynamics. Int J Biochem Cell B 41: 1928–1939.    
• 19. Palmer CS, Osellame LD, Stojanovski D, et al. (2011) The regulation of mitochondrial morphology: intricate mechanisms and dynamic machinery. Cell Signal 23: 1534–1545.    
• 20. Chen H, McCaffery JM, Chan DC (2007) Mitochondrial Fusion Protects against Neurodegeneration in the Cerebellum. Cell 130: 548–562.    
• 21. Twig G, Elorza A, Molina AJ, et al. (2008) Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J 27: 433–446.    
• 22. Meeusen S, DeVay R, Block J, et al. (2006) Mitochondrial inner-membrane fusion and crista maintenance requires the dynamin-related GTPase Mgm1. Cell 127: 383–395.    
• 23. Liesa M, Palacín M, Zorzano A (2009) Mitochondrial dynamics in mammalian health and disease. Physiol Rev 89: 799–845.    
• 24. Alexander C, Votruba M, Pesch U, et al. (2000) OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet 26: 211–215.    
• 25. Detmer S, Chan D (2007) Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol 8: 870–879.    
• 26. Ono T, Isobe K, Nakada K, et al. (2001) Human cells are protected from mitochondrial dysfunction by complementation of DNA products in fused mitochondria. Exp Neurol 28: 272–275.
• 27. Delettre C, Lenaers G, Griffoin JM, et al. (2000) Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet 26: 207–210.    
• 28. Hudson G, Amati-Bonneau P, Blakely EL, et al. (2008) Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain 131: 329–337.    
• 29. Uo T, Dworzak J, Kinoshita C, et al. (2009) Drp1 levels constitutively regulate mitochondrial dynamics and cell survival in cortical neurons. Exp Neurol 218: 274–285.    
• 30. Ishihara N, Nomura M, Jofuku A, et al. (2009) Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. Nat Cell Biol 11: 958–966.    
• 31. Darshi M, Mendiola VL, Mackey MR, et al. (2011) ChChd3, an inner mitochondrial membrane protein, is essential for maintaining crista integrity and mitochondrial function. J Biol Chem 286: 2918–2932.    
• 32. Koch A, Yoon Y, Bonekamp NA, et al. (2005) A Role for Fis1 in Both Mitochondrial and Peroxisomal Fission in Mammalian Cells. Mol Biol Cell 16: 5077–5086.    
• 33. Serasinghe M, Yoon Y (2008) The mitochondrial outer membrane protein hFis1 regulates mitochondrial morphology and fission through self-interaction. Exp Cell Res 314: 3494–3507.    
• 34. Otera H, Wang C, Cleland MM, et al. (2010) Mff is an essential factor for mitochondrial recruitment of Drp1 during mitochondrial fission in mammalian cells. J Cell Biol 191: 1141–1158.    
• 35. Knott AB, Perkins G, Schwarzenbacher R, et al. (2008) Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci 9: 505–518.    
• 36. Niemann A, Ruegg M, Padula VL, et al. (2005) Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease. J Cell Biol 170: 1067–1078.    
• 37. Wagner KM, R ¨ uegg M, Niemann A, et al. (2009) Targeting and function of the mitochondrial fission factor GDAP1 are dependent on its tail-anchor. PloS One 4: e5160.    
• 38. Chen H, Detmer SA, Ewald AJ, et al. (2003) Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 160: 189–200.    
• 39. Wakabayashi J, Zhang Z, Wakabayashi N, et al. (2009) The dynamin-related GTPase Drp1 is required for embryonic and brain development in mice. J Cell Biol 186: 805–816.    
• 40. Chu CT (2019) Mechanisms of selective autophagy and mitophagy: Implications for neurodegenerative diseases. Neurobiol Dis 122: 23–34.    
• 41. Kageyama Y, Zhang Z, Roda R, et al. (2012) Mitochondrial division ensures the survival of postmitotic neurons by suppressing oxidative damage. J Cell Biol 197: 535–551.    
• 42. Lutz AK, Exner N, Fett ME, et al. (2009) Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation. J Biol Chem 284: 22938–22951.    
• 43. Matsuda N, Sato S, Shiba K, et al. (2010) PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol 189: 211–221.    
• 44. Narendra DP, Jin SM, Tanaka A, et al. (2010) PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 8: e1000298.    
• 45. Zhu J, Dagda RK, CHu CT (2011) Monitoring mitophagy in neuronal cell cultures. Methods Mol Biol 793: 325–339.    
• 46. Knott AB, Bossy-Wetzel E (2009) Impairing the Mitochondrial Fission and Fusion Balance: A New Mechanism of Neurodegeneration. Ann N Y Acad Sci 1147: 283–292.
• 47. Martin LJ (2010) Mitochondrial and Cell Death Mechanisms in Neurodegenerative Diseases. Pharmaceuticals 3: 839–915.    
• 48. Corrado M, Scorrano L, Campello S (2012) Mitochondrial Dynamics in Cancer and Neurodegenerative and Neuroinflammatory Disease. Int J Cell Biol 2012.
• 49. Su B, Wang X, Zheng L, et al. (2010) Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta 1802: 135–142.    
• 50. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39: 889–909.    
• 51. Chang D, Nalls MA, Hallgr ´ ımsd ´ ottir IB, et al. (2017) A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat Genet 49: 1511.    
• 52. Olanow C, Tatton W (1999) Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22: 123–144.    
• 53. Koh H, Chung J (2010) PINK1 and Parkin to control mitochondria remodeling. Anat Cell Biol 43: 179–184.    
• 54. Narendra D, Tanaka A, Suen DF, et al. (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183: 795–803.    
• 55. Billingsley KJ, Barbosa IA, Bandr ´ es-Ciga S, et al. (2019) Mitochondria function associated genes contribute to Parkinson's Disease risk and later age at onset. NPJ Parkinson's Dis 5: 8.    
• 56. Panayiotou C, Solaroli N, Johansson M, et al. (2010) Evidence of an intact N-terminal translocation sequence of human mitochondrial adenylate kinase 4. Int J Biochem Cell Biol 42: 62–69.    
• 57. Sai Y, Zou Z, Peng K, et al. (2012) The Parkinson's disease-related genes act in mitochondrial homeostasis. Neurosci Biobehav Rev 36: 2034–2043.    
• 58. Perier C, Vila M (2012) Mitochondrial biology and Parkinson's disease. Cold Spring Harb Perspect Med 2: a009332.
• 59. Comellas G, Lemkau LR, Nieuwkoop AJ, et al. (2011) Structured regions of α -synuclein fibrils include the early-onset Parkinson's disease mutation sites. J Mol Biol 411: 881–895.    
• 60. Ulmer TS, Bax A (2005) Comparison of structure and dynamics of micelle-bound human α -synuclein and Parkinson disease variants. J Biol Chem 280: 43179–43187.    
• 61. Nakamura K, Nemani VM, Azarbal F, et al. (2011) Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein α -synuclein. J Biol Chem 286: 20710–20726.    
• 62. Mori H, Kondo T, Yokochi M, et al. (1998) Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 51: 890–892.    
• 63. Mizuno Y, Hattori N, Yoshino H, et al. (2006) Progress in familial Parkinson's disease. In Parkinson's Disease and Related Disorders, 191–204, Springer.
• 64. Lodi R, Tonon C, Valentino M, et al. (2004) Deficit of in vivo mitochondrial ATP production in OPA1-related dominant optic atrophy. Ann Neurol 56: 719–723.    
• 65. Mayorov V, Lowrey A, Biousse V, et al. (2008) Mitochondrial oxidative phosphorylation in autosomal dominant optic atrophy. BMC Biochem 9: 22.    
• 66. Zanna C, Ghelli A, Porcelli AM, et al. (2008) OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain 131: 352–367.    
• 67. Krajewski K, Lewis R, Fuerst D, et al. (2000) Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 44: 1299–1304.
• 68. Berger P, Young P, Suter U (2002) Molecular cell biology of Charcot-Marie-Tooth disease. Neurogenetics 4: 1–15.    
• 69. Baloh R, Schmidt R, Pestronk A, et al. (2007) Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J Neurosci 27: 422–430.    
• 70. Züchner S, Vance J (2006) Molecular genetics of autosomal-dominant axonal Charcot-Marie-Tooth disease. Neuromolecular Med 8: 63–74.    
• 71. Sme F (2010) MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology 125: 245–256.
• 72. Cerveny K, Tamura Y (2007) Regulation of mitochondrial fusion and division. Trends Cell Biol 17: 563–569.    
• 73. Poole AC, Thomas RE, Andrews LA, et al. (2008) The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci U S A 105: 1638–1643.    
• 74. Yang Y, Ouyang Y, Yang L, et al. (2008) Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci U S A 105: 7070–7075.    
• 75. Valente EM, Abou-Sleiman PM, Caputo V, et al. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304: 1158–1160.    
• 76. Rothfuss O, Fischer H, Hasegawa T, et al. (2009) Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum Mol Genet 18: 3832–3850.    
• 77. Mortiboys H, Thomas KJ, Koopman WJ, et al. (2008) Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann Neurol 64: 555–565.    
• 78. Büttner S, Bitto A, Ring J, et al. (2008) Functional mitochondria are required for α -synuclein toxicity in aging yeast. J Biol Chem 283: 7554–7560.    
• 79. Banerjee K, Sinha M, Pham CLL, et al. (2010) α -Synuclein induced membrane depolarization and loss of phosphorylation capacity of isolated rat brain mitochondria: Implications in Parkinson's disease. FEBS Lett 584: 1571–1576.    
• 80. Yao C, El Khoury R, Wang W, et al. (2010) LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Neurobiol Dis 40: 73–81.    
• 81. Wang X, Yan MH, Fujioka H, et al. (2012) LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 21: 1931–1944.    
• 82. Pich S, Bach D, Briones P, et al. (2005) The Charcot–Marie–Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of OXPHOS system. Hum Mol Genet 14: 1405–1415.    
• 83. Detmer SA, Chan DC (2007) Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations. J Cell Biol 176: 405–414.    
• 84. Niemann A, Berger P, Suter U (2006) Pathomechanisms of Mutant Proteins in Charcot-Marie-Tooth Disease. NeuroMolecular Med 8: 217–242.    
• 85. Noack R, Frede S, Albrecht P, et al. (2012) Charcot–Marie–Tooth disease CMT4A: GDAP1 increases cellular glutathione and the mitochondrial membrane potential. Hum Mol Genet 21: 150–162.    
• 86. Cho D, Nakamura T, Fang J, et al. (2009) S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 324: 102–105.    
• 87. Olichon A, Baricault L, Gas N (2003) Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J Biol Chem 278: 7743–7746.    
• 88. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443: 787.    
• 89. Wang X, Wang W, Li L, et al. (2014) Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta 1842: 1240–1247.    
• 90. Smith MA, Rottkamp CA, Nunomura A, et al. (2000) Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 1502: 139–144.    
• 91. Hirai K, Aliev G, Nunomura A, et al. (2001) Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21: 3017–3023.    
• 92. Sun A, Chen Y (1998) Oxidative stress and neurodegenerative disorders. J Biomed Sci 5: 401–414.    
• 93. Islam MT (2017) Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders. Neurol Res 39: 73–82.    
• 94. Wang X, Su B, Fujioka H, et al. (2008) Dynamin-like protein 1 reduction underlies mitochondrial morphologyanddistributionabnormalitiesinfibroblastsfromsporadicAlzheimer'sdiseasepatients. Am J Pathol 173: 470–482.    
• 95. Wang X, Su B, Siedlak SL, et al. (2008) Amyloid- β overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci 105: 19318–19323.    
• 96. Martin M, Hurd D, Saxton W (1999) Kinesins in the nervous system. Cell Mol Life Sci 56: 200–216.    
• 97. Schnapp BJ, Reese TS (1989) Dynein is the motor for retrograde axonal transport of organelles. Proc Natl Acad Sci U S A 86: 1548–1552.    
• 98. Tabb JS, Molyneaux BJ, Cohen DL, et al. (1998) Transport of ER vesicles on actin filaments in neurons by myosin V. J Cell Sci 111: 3221–3234.
• 99. Ligon LA, Steward O (2000) Role of microtubules and actin filaments in the movement of mitochondria in the axons and dendrites of culture hippocampal neurons. Journal Comp Neur 427: 351–361.    
• 100. Hirokawa N (1998) Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science 279: 519–526.    
• 101. Gross SP (2004) Hither and yon: A review of bi-directional microtubule-based transport. Phys Biol 1: R1–R11.    
• 102. Ligon LA, Tokito M, Finklestein JM, et al. (2004) A direct interaction between cytoplasmic dynein and kinesin I may coordinate motor activity. J Biol Chem 279: 19201–19208.    
• 103. Stowers R, Megeath L, G ´ orska-Andrzejak J, et al. (2002) Axonal transport of mitochondria to synapses depends on milton, a novel Drosophila protein. Neuron 36: 1063–1077.    
• 104. Guo X, Macleod G, Wellington A, et al. (2005) The GTPase dMiro is required for axonal transport of mitochondria to Drosophila synapses. Neuron 47: 379–393.    
• 105. Russo G, Louie K, Wellington A, et al. (2009) Drosophila Miro is required for both anterograde and retrograde axonal mitochondrial transport. J Neurosci 29: 5443–5455.    
• 106. Koutsopoulos OS, Laine D, Osellame L, et al. (2010) Human miltons associate with mitochondria and induce microtubule-dependent remodeling of mitochondrial networks. Biochim Biophys Acta 1803: 564–574.    
• 107. Wang X, Winter D, Ashrafi G, et al. (2011) PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 147: 893–906.    
• 108. Hsieh CH, Shaltouki A, Gonzalez AE, et al. (2016) Functional impairment in miro degradation and mitophagy is a shared feature in familial and sporadic Parkinson's disease. Cell Stem Cell 19: 709–724.    
• 109. Baloh RH (2008) Mitochondrial dynamics and peripheral neuropathy. Neuroscientist 14: 12–18.    
• 110. Misko A, Jiang S, Wegorzewska I, et al. (2010) Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. J Neurosci 30: 4232–4240.    
• 111. Ikenaka K, Katsuno M, Kawai K, et al. (2012) Disruption of axonal transport in motor neuron diseases. Int J Mol Sci 13: 1225–1238.    
• 112. Mandal A, Drerup CM (2019) Axonal transport and mitochondrial function in neurons. Front Cell Neurosci 13: 373.
• 113. Ader NR (2016) Seeking an in vivo neuronal context for the PINK1/Parkin pathway. J Neurosci 36: 11165–11167.    
• 114. Metaxakis A, Ploumi C, Tavernarakis N (2018) Autophagy in age-associated neurodegeneration. Cells 7: 37.    
• 115. Rintoul GL, Reynolds IJ (2010) Mitochondrial trafficking and morphology in neuronal injury. Biochim Biophys Acta 1802: 143–150.    
• 116. Chang DT, Reynolds IJ (2006) Mitochondrial trafficking and morphology in healthy and injured neurons. Prog Neurobiol 80: 241–268.    
• 117. Weihofen A, Thomas K, Ostaszewski B, et al. (2009) Pink1 forms a multiprotein complex with miro and milton, linking Pink1 function to mitochondrial trafficking. Biochemistry 48: 2045–2052.    
• 118. Yang F, Jiang Q, Zhao J, et al. (2005) Parkin stabilizes microtubules through strong binding mediated by three independent domains. J Biol Chem 280: 17154–17162.    
• 119. Lee H, Khoshaghideh F, Lee S, et al. (2006) Impairment of microtubule-dependent trafficking by overexpression of α-synuclein. European J Neurosci 24: 3153–3162.    
• 120. Gillardon F (2009) Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability-A point of convergence in Parkinsonian neurodegeneration? J Neurochem 10: 1514–1522.
• 121. Braak E, Sandmann-Keil D, Rüb U, et al. (2001) α -Synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol 101: 195–201.    
• 122. Liu S, Sawada T, Lee S, et al. (2012) Parkinson's disease–associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. PLoS Genet 8: e1002537.    
• 123. Chu Y, Morfini GA, Langhamer LB, et al. (2012) Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 135: 2058–2073.    
• 124. Abeliovich A, Gitler AD (2016) Defects in trafficking bridge Parkinson's disease pathology and genetics. Nature 539: 207.    
• 125. Züchner S, Mersiyanova I, Muglia M, et al. (2004) Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 36: 449–451.    
• 126. Patzk ´ o A, Shy ME (2011) Update on Charcot-Marie-Tooth Disease. Curr Neurol Neurosci Rep 11: 78–88.    
• 127. Shy M (2004) Charcot-Marie-Tooth disease: An update. Curr Opin Neurol 17: 579–585.    
• 128. Loiseau D, Chevrollier A, Verny C, et al. (2007) Mitochondrial coupling defect in Charcot–Marie–Tooth type 2A disease. Ann Neurol 61: 315–323.    
• 129. Stokin G, Lillo C, Falzone T, et al. (2005) Axonopathy and transport deficits early in the pathogenesis of Alzheimer's diseases. Science 307: 1282–1288.    
• 130. Wang X, Su B, Lee H (2009) Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 29: 9090–9103.    
• 131. Vickers JC, King AE, Woodhouse A, et al. (2009) Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system. Brain Res Bull 80: 217–223.    
• 132. De Vos K, Chapman A, Tennant M, et al. (2007) Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum Mol Genet 16: 2720–2728.    
• 133. Shi P, Ström A, Gal J, et al. (2010) Effects of ALS-related SOD1 mutants on dynein- and KIF5-mediated retrograde and anterograde axonal transport. Biochim Biophys Acta 1802: 707–716.    
• 134. Chang D, Rintoul G, Pandipati S, et al. (2006) Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol Dis 22: 388–400.    
• 135. Trushina E, Dyer R, Badger J, et al. (2004) Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol 24: 8195–8209.    
• 136. Bach D, Pich S, Soriano FX (2003) Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism: a novel regulatory mechanism altered in obesity. J Biol Chem 278: 17190–17197.    
• 137. Chen H, Chomyn A, Chan DC (2005) Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem 280: 26185–26192.    
• 138. Van Laar VS, Berman SB (2013) The interplay of neuronal mitochondrial dynamics and bioenergetics: implications for Parkinson's disease. Neurobiol Dis 51: 43–55.    
• 139. Coskun P, Wyrembak J, Schriner SE, et al. (2012) A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim Biophys Acta 1820: 553–564.    
• 140. Ryan BJ, Hoek S, Fon EA, et al. (2015) Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. Trends Biochem Sci 40: 200–210.    
• 141. Van Laar VS, Berman SB (2009) Mitochondrial dynamics in Parkinson's disease. Exp Neurol 218: 247–256.    
• 142. Requejo-Aguilar R, Bolaños JP (2016) Mitochondrial control of cell bioenergetics in Parkinson's disease. Free Radic Biol Med 100: 123–137.    
• 143. Abramov AY, Gegg M, Grunewald A, et al. (2011) Bioenergetic consequences of PINK1 mutations in Parkinson disease. PLoS One 6: e25622.    
• 144. Lansbury PT, Lashuel HA (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443: 774–779.    
• 145. Jain S, Wood NW, Healy DG (2005) Molecular genetic pathways in Parkinson's disease: A review. Clin Sci 109: 355–364.    
• 146. Winklhofer KF, Haass C (2010) Mitochondrial dysfunction in Parkinson's disease. Biochim Biophy Acta 1802: 29–44.    
• 147. Chen C, Turnbull DM, Reeve AK (2019) Mitochondrial Dysfunction in Parkinson's Disease-Cause or Consequence? Biology 8: 38.    
• 148. Diot A, Morten K, Poulton J (2016) Mitophagy plays a central role in mitochondrial ageing. Mamm Genome 27: 381–395.    
• 149. Noda S, Sato S, Fukuda T, et al. (2019) Loss of Parkin contributes to mitochondrial turnover and dopaminergic neuronal loss in aged mice. Neurobiol Dis 136: 104717.
• 150. Fivenson EM, Lautrup S, Sun N, et al. (2017) Mitophagy in neurodegeneration and aging. Neurochem Int 109: 202–209.    
• 151. Ebrahimi-Fakhari D, Wahlster L, McLean PJ (2012) Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol 124: 153–172.    
• 152. Wang W, Wang X, Fujioka H, et al. (2016) Parkinson's disease–associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes. Nat Med 22: 54.    
• 153. Singleton A, Farrer M, Johnson J, et al. (2003) α -Synuclein locus triplication causes Parkinson's disease. Science 302: 841–841.    
• 154. Regev A, Silverman W, Shapiro E (2001) Representation and simulation of biochemical processes using the π-calculus process algebra. Pac Symp Biocomput, 459–470.
• 155. Bonzanni N, Feenstra KA, Fokkink W, et al. (2009) What can formal methods bring to systems biology? In International Symposium on Formal Methods, Springer, 16–22.
• 156. Theocharopoulou G, Giannakis K, Andronikos T (2015) The mechanism of splitting mitochondria in terms of membrane automata. In 2015 IEEE International Symposium on Signal Processing and Information Technology (ISSPIT) IEEE, 397–402.
• 157. Theocharopoulou G, Vlamos P (2015) Modeling protein misfolding in Charcot–Marie–Tooth disease. In GeNeDis 2014, Springer, 91–102.
• 158. Theocharopoulou G, Bobori C, Vlamos P (2017) Formal models of biological systems. In GeNeDis 2016, Springer, 325–338.
• 159. Corona JC, Duchen MR (2015) Impaired mitochondrial homeostasis and neurodegeneration: towards new therapeutic targets? J Bioenerg Biomembr 47: 89–99.    
• 160. Kitada T, Asakawa S, Hattori N, et al. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605.    
• 161. Healy DG, Falchi M, O'Sullivan SS, et al. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7: 583–590.    
• 162. Peng JY, Lin CC, Chen YJ, et al. (2011) Automatic morphological subtyping reveals new roles of caspases in mitochondrial dynamics. PLoS Comput Biol 7: e1002212.    
• 163. Tronstad KJ, Nooteboom M, Nilsson LI, et al. (2014) Regulation and quantification of cellular mitochondrial morphology and content. Curr Pharm Des 20: 5634–5652.    
• 164. Zamponi N, Zamponi E, Cannas SA, et al. (2018) Mitochondrial network complexity emerges from fission/fusion dynamics. Sci Rep 8: 363.    
• 165. Shah SI, Paine JG, Perez C, et al. (2019) Mitochondrial fragmentation and network architecture in degenerative diseases. PloS One 14: e0223014.    
• 166. Toglia P, Demuro A, Mak DOD, et al. (2018) Data-driven modeling of mitochondrial dysfunction in Alzheimer's disease. Cell Calcium 76: 23–35.    
• 167. Dukes AA, Bai Q, Van Laar VS, et al. (2016) Live imaging of mitochondrial dynamics in CNS dopaminergic neurons in vivo demonstrates early reversal of mitochondrial transport following MPP+ exposure. Neurobiol Dis 95: 238–249.    
• 168. Alexiou A, Vlamos P (2012) Evidence for early identification of Alzheimer's disease. In arXiv preprint arXiv:1209.4223
• 169. Lundkvist J, Naslund J (2007) Gamma-secretase: A complex target for Alzheimer's disease. Curr Opin Pharmacol 7: 112–118.    
• 170. Evin G, Kenche V (2007) BACE inhibitors as potential therapeutics for Alzheimer's disease. Recent Pat CNS Drug Discov 2: 188–199.
• 171. Alexiou A, Vlamos P, Rekkas J (2011) Modeling the mitochondrial dysfunction in neurogenerative diseases due to high H+ concentration. Bioinformation 6: 173–175.    
• 172. Miller KE, Sheetz MP (2004) Axonal mitochondrial transport and potential are correlated. J Cell Sci 117: 2791–2804.    
• 173. Oliveira JMA (2011) Techniques to investigate neuronal mitochondrial function and its pharmacological modulation. Curr Drug Targets 12: 762–773.    
• 174. Twig G, Hyde B, Shirihai OS (2008) Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view. Biochim Biophys Acta 1777: 1092–1097.    
• 175. Onyango IG, Dennis J, Khan SM (2016) Mitochondrial dysfunction in Alzheimer's disease and the rationale for bioenergetics based therapies. Aging Dis 7: 201–214.    

show all references